시장보고서
상품코드
1957730

방사성 의약품 시장 보고서(2026년)

Radiopharmaceuticals Global Market Report 2026

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

방사성 의약품 시장 규모는 최근 급성장하고 있습니다. 2025년 73억 달러에서 2026년에는 82억 5,000만 달러에 이르고, CAGR 13.0%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 핵의학 영상기술의 보급, 암 진단율 증가, 방사성 동위원소의 가용성, 병원 내 핵의학 부서의 확대, 진단용 약품의 규제 당국 승인 등에 기인하는 것으로 보입니다.

방사성 의약품 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 136억 8,000만 달러에 이르고, CAGR은 13.5%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 정밀 종양학의 발전, 표적 방사선 치료 수요 증가, 진단 영상 센터의 확대, 사이클로트론 설비 투자, 동위원소 생산 기술의 발전 등을 들 수 있습니다. 예측 기간의 주요 동향으로는 종양학 분야에서의 방사성의약품 사용 증가, 테라노스틱스(치료 진단) 용도의 성장, PET 및 SPECT 이미징의 확대, 표적 방사선 치료의 개발 증가, 핵의학 인프라의 개선 등을 들 수 있습니다.

암 및 심혈관 질환의 유병률 증가에 따라 방사성의약품 시장에 대한 수요 증가가 예상됩니다. 방사성의약품은 기존 의약품에 비해 안전하고 효과적인 치료 옵션으로 인지도가 높아지고 있습니다. 표적치료, 정밀치료 등의 장점으로 방사선과 의사가 암이나 심혈관 질환 치료에 있어 큰 우위를 점할 수 있다는 점이 특징입니다. 암은 전 세계 사망원인 2위이며, 전 세계 사망자 6명 중 1명이 암으로 사망합니다. 예를 들어, 프랑스에 본부를 둔 전문 기관인 국제암연구소(IARC)에 따르면, 2022년에는 전 세계적으로 약 2,000만 건의 신규 암 발생과 970만 건의 암 관련 사망이 보고될 것으로 예상하고 있습니다. 이 수치는 2040년까지 연간 신규 확진자 수 2,990만 명, 사망자 수 1,530만 명으로 증가할 것으로 예측됩니다. 그 결과, 암과 심혈관 질환의 발생률 증가는 치료에 사용되는 방사성의약품 수요를 크게 증가시킬 것으로 예측됩니다.

방사성의약품 시장에서 활동하는 주요 기업들은 혁신을 가속화하고 첨단 진단 및 치료 솔루션에 대한 접근성을 확대하기 위해 전략적 제휴를 강화하고 있습니다. 이러한 협력은 방사성의약품 개발 강화, 지역적 제조 능력 향상, 정밀 영상진단 및 표적치료에 대한 수요 증가에 대응하기 위한 것입니다. 예를 들어, 2023년 6월 미국 피츠버그 대학 의료센터(UPMC)는 파마로직 홀딩스(PharmaLogic Holdings Corporation)와 제휴하여 피츠버그 시설에서 새로운 방사성의약품의 공동 개발 및 제조를 시작했습니다. 이번 제휴는 주변 지역에서는 쉽게 구할 수 없는 첨단 진단 및 치료제를 환자와 의료진이 보다 폭넓게 이용할 수 있도록 하는 것을 목표로 하고 있습니다. 비독점 계약에 따라 UPMC와 파마로직은 실험 단계의 방사성의약품을 임상 적용 가능한 제품으로 전환하여 혁신적인 핵의학 치료제의 광범위한 상업화 및 신속한 보급을 지원할 예정입니다.

자주 묻는 질문

  • 방사성 의약품 시장 규모는 어떻게 변화하고 있나요?
  • 방사성 의약품 시장의 성장 요인은 무엇인가요?
  • 방사성 의약품의 수요 증가 원인은 무엇인가요?
  • 방사성 의약품 시장에서 주요 기업들은 어떤 전략을 취하고 있나요?
  • 방사성 의약품 개발을 위한 최근 제휴 사례는 무엇인가요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

LSH 26.03.17

Radiopharmaceuticals are medications that contain radioactive substances and are used for the diagnosis or treatment of diseases, including cancer. Also known as radioactive drugs, they are employed to identify specific illnesses or detect medical conditions. These medications can be administered to patients through various methods, such as injection, oral intake, or delivery into areas like the eye or bladder.

The primary types of radiopharmaceuticals include diagnostic, therapeutic, and others. Radiopharmaceutical therapeutics involve the delivery of radioactive atoms to targets associated with tumors. These agents are used across applications such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others, and are utilized by hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and other healthcare facilities.

Tariffs have influenced the radiopharmaceuticals market by increasing costs related to radioisotope imports, nuclear medicine equipment, and specialized transportation systems. Diagnostic and therapeutic radiopharmaceutical segments are particularly affected due to time-sensitive supply chains. North america and europe face operational challenges because of cross-border isotope dependency. However, tariffs are driving investments in domestic isotope production and regional cyclotron facilities. These efforts are improving supply reliability and supporting long-term market growth.

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiopharmaceuticals market size has grown rapidly in recent years. It will grow from $7.3 billion in 2025 to $8.25 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to adoption of nuclear imaging technologies, growth in cancer diagnosis rates, availability of radioisotopes, hospital-based nuclear medicine expansion, regulatory approvals for diagnostic agents.

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $13.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in precision oncology, rising demand for targeted radiotherapies, expansion of diagnostic imaging centers, investments in cyclotron infrastructure, technological advancements in isotope production. Major trends in the forecast period include rising use of radiopharmaceuticals in oncology, growth of theranostics applications, expansion of pet and spect imaging, increasing development of targeted radiotherapies, improved nuclear medicine infrastructure.

The growing prevalence of cancer and cardiovascular diseases is expected to increase demand for the radiopharmaceuticals market. Radiopharmaceuticals are gaining recognition as safe and effective therapeutic options compared with conventional medicines. They offer significant advantages to radiologists in the treatment of cancer and cardiovascular conditions due to benefits such as targeted therapy and precision treatment. Cancer is the second leading cause of death globally, accounting for approximately one in six deaths worldwide. For example, in April 2024, according to the International Agency for Research on Cancer (IARC), a France-based specialized agency, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported worldwide in 2022. These figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the increasing incidence of cancer and cardiovascular diseases is expected to significantly boost demand for radiopharmaceuticals used in their treatment.

Major companies operating in the radiopharmaceuticals market are increasingly engaging in strategic partnerships to accelerate innovation and broaden access to advanced diagnostic and therapeutic solutions. These collaborations aim to strengthen radiopharmaceutical development, enhance regional manufacturing capabilities, and meet the rising demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to jointly develop and manufacture new radiopharmaceuticals at a facility in Pittsburgh. This partnership is intended to expand access for patients and clinicians to advanced diagnostic and therapeutic agents that are not readily available in surrounding regions. Under the non-exclusive agreement, UPMC and PharmaLogic will convert experimental radiopharmaceuticals into clinically viable products, supporting broader commercialization and faster adoption of innovative nuclear medicine treatments.

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed the acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to strengthen its position in the growing field of radioligand therapies, which offer promising advancements in cancer treatment. Point Biopharma specializes in radiopharmaceutical development, complementing Lilly's oncology portfolio and supporting efforts to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for multiple cancer types.

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, UJV Rez, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacybapy-Monrol Nuclear Products, NTP Radioisotopes.

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Diagnostic; Therapeutic
  • 2) By Application: Oncology; Cardiology; Gastroenterology; Neuroendocrinology; Musculoskeletal; Respiratory; Nephrology; Other Applications
  • 3) By End User: Hospitals And Ambulatory Surgical Centers; Diagnostic Centers; Cancer Research Institutes
  • Subsegments:
  • 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
  • Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE); IBA Group; Bayer AG; Lantheus Medical Imaging Inc.; Bracco Imaging S.p.A.; Eckert & Ziegler; Nihon Medi-Physics Co. Ltd.; Fujifilm Corporation; ANSTO; Yantai Dongcheng Pharmaceutical Group Co. Ltd.; Bracco Imaging SpA.; Canon Inc.; China Isotope & Radiation Corporation (CIRC); Alliance Medical; Advanced Accelerator Applications; JSC Isotope; Pharm-Sintez; Synektik SA; Polatom; RadioMedic sro; UJV Rez; Actinium Pharmaceuticals Inc.; Alseres Pharmaceuticals Inc.; Avid Radiopharmaceuticals; Fusion Pharmaceuticals; Peregrine Pharmaceuticals Inc.; PETNET Solutions Inc.; Positron Corporation; Triad Isotopes Inc.; Telix Pharmaceuticals; Rosatom; Alliance Medical Group; Hologic Inc.; Segami Corporation; Eczacybapy-Monrol Nuclear Products; NTP Radioisotopes.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Radiopharmaceuticals Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Radiopharmaceuticals Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Radiopharmaceuticals Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Radiopharmaceuticals Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Rising Use Of Radiopharmaceuticals In Oncology
    • 4.2.2 Growth Of Theranostics Applications
    • 4.2.3 Expansion Of PET And SPECT Imaging
    • 4.2.4 Increasing Development Of Targeted Radiotherapies
    • 4.2.5 Improved Nuclear Medicine Infrastructure

5. Radiopharmaceuticals Market Analysis Of End Use Industries

  • 5.1 Hospitals And Ambulatory Surgical Centers
  • 5.2 Diagnostic Imaging Centers
  • 5.3 Cancer Treatment Centers
  • 5.4 Nuclear Medicine Clinics
  • 5.5 Research Institutes

6. Radiopharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Radiopharmaceuticals Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Radiopharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Radiopharmaceuticals Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Radiopharmaceuticals Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Radiopharmaceuticals Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Radiopharmaceuticals Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Radiopharmaceuticals Market Segmentation

  • 9.1. Global Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Diagnostic, Therapeutic
  • 9.2. Global Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
  • 9.3. Global Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
  • 9.4. Global Radiopharmaceuticals Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 9.5. Global Radiopharmaceuticals Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Alpha Emitters, Beta Emitters, Brachytherapy

10. Radiopharmaceuticals Market Regional And Country Analysis

  • 10.1. Global Radiopharmaceuticals Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Radiopharmaceuticals Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Radiopharmaceuticals Market

  • 11.1. Asia-Pacific Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Radiopharmaceuticals Market

  • 12.1. China Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Radiopharmaceuticals Market

  • 13.1. India Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Radiopharmaceuticals Market

  • 14.1. Japan Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Radiopharmaceuticals Market

  • 15.1. Australia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Radiopharmaceuticals Market

  • 16.1. Indonesia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Radiopharmaceuticals Market

  • 17.1. South Korea Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Radiopharmaceuticals Market

  • 18.1. Taiwan Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Radiopharmaceuticals Market

  • 19.1. South East Asia Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Radiopharmaceuticals Market

  • 20.1. Western Europe Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Radiopharmaceuticals Market

  • 21.1. UK Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Radiopharmaceuticals Market

  • 22.1. Germany Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Radiopharmaceuticals Market

  • 23.1. France Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Radiopharmaceuticals Market

  • 24.1. Italy Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Radiopharmaceuticals Market

  • 25.1. Spain Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Radiopharmaceuticals Market

  • 26.1. Eastern Europe Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Radiopharmaceuticals Market

  • 27.1. Russia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Radiopharmaceuticals Market

  • 28.1. North America Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Radiopharmaceuticals Market

  • 29.1. USA Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Radiopharmaceuticals Market

  • 30.1. Canada Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Radiopharmaceuticals Market

  • 31.1. South America Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Radiopharmaceuticals Market

  • 32.1. Brazil Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Radiopharmaceuticals Market

  • 33.1. Middle East Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Radiopharmaceuticals Market

  • 34.1. Africa Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Radiopharmaceuticals Market Regulatory and Investment Landscape

36. Radiopharmaceuticals Market Competitive Landscape And Company Profiles

  • 36.1. Radiopharmaceuticals Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Radiopharmaceuticals Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Radiopharmaceuticals Market Company Profiles
    • 36.3.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. General Electric Company (GE) Overview, Products and Services, Strategy and Financial Analysis

37. Radiopharmaceuticals Market Other Major And Innovative Companies

  • IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope

38. Global Radiopharmaceuticals Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Radiopharmaceuticals Market

40. Radiopharmaceuticals Market High Potential Countries, Segments and Strategies

  • 40.1 Radiopharmaceuticals Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Radiopharmaceuticals Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Radiopharmaceuticals Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제